3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Not yet recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Melanoma
6
Crohn Disease
4
Colitis, Ulcerative
4
Colitis
4
Carcinoma, Non-Small-Cell Lung
4
Lung Neoplasms
3
Inflammatory Bowel Diseases
3
Arthritis, Rheumatoid
3
Urogenital Neoplasms
2
Inflammation
2
Hematologic Neoplasms
2
Graft vs Host Disease
2
Fatigue
2
Depressive Disorder, Major
2
Depression
2
Cachexia
2
Anorexia
2
Vasculitis
1
Takayasu Arteritis
1
Syndrome
1
Stroke
1
Stevens-Johnson Syndrome
1
Skin Neoplasms
1
Recurrence
1
Rare Diseases
1
Pemphigoid, Benign Mucous Membrane
1
Pancreatic Neoplasms
1
Lymphoma
1
Kidney Transplantation
1
Hypertension
1
Interventions
Mycophenolic Acid
2
vedolizumab
1
bavituximab
1
Ursodeoxycholic Acid
1
Steroids
1
Sorafenib
1
Sofosbuvir
1
Ribavirin
1
Prednisone
1
Photopheresis
1
Methylprednisolone Hemisuccinate
1
Methylprednisolone
1
Methoxsalen
1
Infliximab
1
Azathioprine
1
Adrenal Cortex Hormones
1
3-(2-(2-tert-butylphenylaminooxalyl)aminopropionylamino)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Hepatitis
×
Infliximab
×
Clear all
NCT07619898
2026-06-02
PHOENIX-ECP
Therakos LLC
Phase 2
Not yet recruiting
112 enrolled